Patents by Inventor Andrew T. Bruce

Andrew T. Bruce has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240108657
    Abstract: The invention is directed to isolated renal cells, including tubular and erythropoietin (EPO)-producing kidney cell populations, and methods of isolating and culturing the same, as well as methods of treating a subject in need with the cell populations.
    Type: Application
    Filed: October 10, 2023
    Publication date: April 4, 2024
    Inventors: Sharon C. Presnell, Andrew T. Bruce, Shay M. Wallace, Sumana Choudhury, Russell W. Kelley, Manuel J. Jayo, Jessica J. Reinsch, Patricia D. Tatsumi, Timothy A. Bertram, Eric S. Werdin, Oluwatoyin A. Knight, H. Scott Rapoport, Roger M. Ilagan
  • Publication number: 20210238600
    Abstract: The present invention concerns bioactive renal cell populations, renal cell constructs, and methods of making and using the same.
    Type: Application
    Filed: February 9, 2021
    Publication date: August 5, 2021
    Inventors: Timothy A. Bertram, Roger M. Ilagan, Russell W. Kelley, Sharon C. Presnell, Sumana Choudhury, Andrew T. Bruce, Christopher W. Genheimer, Bryan R. Cox, Kelly I. Guthrie, Joydeep Basu, Shay M. Wallace, Eric S. Werdin, Oluwatoyin A. Knight, Namrata D. Sangha, John W. Ludlow, Craig R. Halberstadt, Richard Payne, Neil F. Robins, Jr., Darell McCoy, Deepak Jain, Manuel J. Jayo, Elias A. Rivera, Thomas Spencer, Benjamin Watts
  • Patent number: 11066666
    Abstract: The present invention concerns bioactive renal cells populations, renal cell constructs, and methods of making and using the same.
    Type: Grant
    Filed: March 19, 2018
    Date of Patent: July 20, 2021
    Assignee: inRegen
    Inventors: Timothy A. Bertram, Roger M. Ilagan, Russell W. Kelley, Sharon C. Presnell, Sumana Choudhury, Andrew T. Bruce, Christopher W. Genheimer, Bryan R. Cox, Kelly I. Guthrie, Joydeep Basu, Shay M. Wallace, Eric Werdin, Oluwatoyin A. Knight, Namrata D. Sangha, John W. Ludlow, Craig R. Halberstadt, Richard Payne, Neil F. Robins, Darell McCoy, Deepak Jain, Manuel J. Jayo, Elias A. Rivera, Thomas Spencer, Benjamin Watts
  • Publication number: 20190117695
    Abstract: The invention is directed to isolated renal cells, including tubular and erythropoietin (EPO)-producing kidney cell populations, and methods of isolating and culturing the same, as well as methods of treating a subject in need with the cell populations.
    Type: Application
    Filed: October 15, 2018
    Publication date: April 25, 2019
    Inventors: Sharon C. Presnell, Andrew T. Bruce, Shay M. Wallace, Sumana Choudhury, Russell W. Kelley, Manuel J. Jayo, Jessica J. Reinsch, Patricia D. Tatsumi, Timothy Bertram, Eric S. Werdin, Oluwatoyin A. Knight, H. Scott Rapoport, Roger M. Ilagan
  • Publication number: 20180282726
    Abstract: The present invention concerns bioactive renal cells populations, renal cell constructs, and methods of making and using the same.
    Type: Application
    Filed: March 19, 2018
    Publication date: October 4, 2018
    Inventors: Timothy A. Bertram, Roger M. Ilagan, Russell W. Kelley, Sharon C. Presnell, Sumana Choudhury, Andrew T. Bruce, Christopher W. Genheimer, Bryan R. Cox, Kelly I. Guthrie, Joydeep Basu, Shay M. Wallace, Eric Werdin, Oluwatoyin A. Knight, Namrata D. Sangha, John W. Ludlow, Craig R. Halberstadt, Richard Payne, Neil F. Robins, Darrell McCoy, Deepak Jain, Manuel J. Jayo, Elias A. Rivera, Thomas Spencer, Benjamin Watts
  • Patent number: 10077442
    Abstract: The present invention concerns bioactive renal cell populations, renal cell constructs, and methods of making and using the same.
    Type: Grant
    Filed: May 12, 2011
    Date of Patent: September 18, 2018
    Assignee: inRegen
    Inventors: Timothy A. Bertram, Roger M. Ilagan, Russell W. Kelley, Sharon C. Presnell, Sumana Choudhury, Andrew T. Bruce, Christopher W. Genheimer, Bryan R. Cox, Kelly I. Guthrie, Joydeep Basu, Shay M. Wallace, Eric Werdin, Oluwatoyin A. Knight, Namrata D. Sangha, John W. Ludlow, Craig R. Halberstadt, Richard Payne, Neil F. Robins, Darell McCoy, Deepak Jain, Manuel J. Jayo, Elias A. Rivera, Thomas Spencer, Benjamin Watts
  • Patent number: 10030242
    Abstract: The present invention concerns bioactive renal cell populations, renal cell constructs, and methods of making and using the same.
    Type: Grant
    Filed: May 12, 2011
    Date of Patent: July 24, 2018
    Assignee: InRegen
    Inventors: Timothy A. Bertram, Roger M. Ilagan, Russell W. Kelley, Sharon C. Presnell, Sumana Choudhury, Andrew T. Bruce, Christopher W. Genheimer, Bryan R. Cox, Kelly I. Guthrie, Joydeep Basu, Shay M. Wallace, Eric Werdin, Oluwatoyin A. Knight, Namrata D. Sangha, John W. Ludlow, Craig R. Halberstadt, Richard Payne, Neil F. Robins, Darell McCoy, Deepak Jain, Manuel J. Jayo, Elias A. Rivera, Thomas Spencer, Benjamin Watts
  • Publication number: 20170205398
    Abstract: The present invention concerns bioactive renal cell populations, in particular a B2 cell population comprising an enriched population of tubular cells and wherein the renal cell population is depleed of a B1 cell population, renal cell constructs, and methods of screening test agents using the bioactive renal cell populations.
    Type: Application
    Filed: September 16, 2016
    Publication date: July 20, 2017
    Inventors: ANDREW T. BRUCE, RUSSELL W. KELLEY, TIMOTHY A. BERTRAM, SUMANA CHOUDHURY
  • Publication number: 20170096641
    Abstract: Hepatic progenitors comprise two populations of human hepatic stem cells, primitive and proximal hepatic stem cells, and two populations of committed progenitors, one for biliary cells and one for hepatocytes. Human primitive hepatic stem cells are a very small fraction of the liver cell population and give rise to proximal hepatic stem cells constituting a much larger fraction of the liver. Human proximal hepatic stem cells give rise to biliary and hepatocyte committed progenitors. Primitive and proximal stem cells are the primary stem cells for the human liver. Human primitive hepatic stem cells may be isolated by immunoselection from human livers or culturing human liver cells under conditions which select for a human primitive hepatic stem cell. Proximal hepatic stem cells may be isolated by immunoselection, or by culturing human liver cells under conditions which include a developmental factor.
    Type: Application
    Filed: October 12, 2016
    Publication date: April 6, 2017
    Applicants: Vesta Therapeutics Inc., University of North Carolina at Chapel Hill
    Inventors: Lola M. REID, Nicholas MOSS, Mark E. FURTH, John W. LUDLOW, Andrew T. BRUCE
  • Publication number: 20140308695
    Abstract: The present invention concerns bioactive renal cell populations, in particular a B2 cell population comprising an enriched population of tubular cells and wherein the renal cell population is depleted of a B1 cell population, renal cell constructs, and methods of screening test agents using the bioactive renal cell populations.
    Type: Application
    Filed: November 5, 2012
    Publication date: October 16, 2014
    Inventors: Andrew T. Bruce, Russell W. Kelley, Timothy A. Bertram, Sumana Choudhury
  • Publication number: 20140302601
    Abstract: Hepatic progenitors comprise two populations of human hepatic stem cells, primitive and proximal hepatic stem cells, and two populations of committed progenitors, one for biliary cells and one for hepatocytes. Human primitive hepatic stem cells are a very small fraction of the liver cell population and give rise to proximal hepatic stem cells constituting a much larger fraction of the liver. Human proximal hepatic stem cells give rise to biliary and hepatocyte committed progenitors. Primitive and proximal stem cells are the primary stem cells for the human liver. Human primitive hepatic stem cells may be isolated by immunoselection from human livers or culturing human liver cells under conditions which select for a human primitive hepatic stem cell. Proximal hepatic stem cells may be isolated by immunoselection, or by culturing human liver cells under conditions which include a developmental factor.
    Type: Application
    Filed: April 3, 2014
    Publication date: October 9, 2014
    Applicants: University of North Carolina at Chapel Hill, Vesta Therapeutics Inc.
    Inventors: Lola M. REID, Nicholas MOSS, Mark E. FURTH, John W. LUDLOW, Andrew T. BRUCE
  • Patent number: 8691523
    Abstract: Hepatic progenitors comprise two populations of human hepatic stem cells, primitive and proximal hepatic stem cells, and two populations of committed progenitors, one for biliary cells and one for hepatocytes. Human primitive hepatic stem cells are a very small fraction of the liver cell population and give rise to proximal hepatic stem cells constituting a much larger fraction of the liver. Human proximal hepatic stem cells give rise to biliary and hepatocyte committed progenitors. Primitive and proximal stem cells are the primary stem cells for the human liver. Human primitive hepatic stem cells may be isolated by immunoselection from human livers or culturing human liver cells under conditions which select for a human primitive hepatic stem cell. Proximal hepatic stem cells may be isolated by immunoselection, or by culturing human liver cells under conditions which include a developmental factor.
    Type: Grant
    Filed: December 12, 2006
    Date of Patent: April 8, 2014
    Assignees: Vesta Therapeautics, Inc., University of North Carolina at Chapel Hill
    Inventors: Lola M. Reid, Nicholas Moss, Mark E. Furth, John W. Ludlow, Andrew T. Bruce
  • Publication number: 20110224800
    Abstract: The present invention relates to the regeneration, reconstruction, augmentation or replacement of organs or tissue structures using scaffolds and cells derived from peritoneal tissue.
    Type: Application
    Filed: March 8, 2011
    Publication date: September 15, 2011
    Inventors: John W. Ludlow, Kelly I. Guthrie, Andrew T. Bruce, Kenny Johnson
  • Publication number: 20100112689
    Abstract: The present invention is directed toward a method for obtaining from whole liver or a resection thereof a population of cells comprising viable, functional liver cells enriched in hepatocytes and hepatocyte stem/progenitor cells, compositions thereof, and uses therefore. Compositions include a composition of liver cells enriched in hepatocytes and hepatocyte stem/progenitor cells and a pharmaceutical composition thereof. Uses include treatment of liver diseases, regeneration of liver, toxicity testing, and liver assist devices.
    Type: Application
    Filed: May 13, 2009
    Publication date: May 6, 2010
    Inventors: John W. Ludlow, Mark E. Furth, Andrew T. Bruce, Lola M. Reid, Robert L. Susick, JR.
  • Patent number: 7413897
    Abstract: Hepatic progenitors comprise two populations of human hepatic stem cells, primitive and proximal hepatic stem cells, and two populations of committed progenitors, one for biliary cells and one for hepatocytes. Human primitive hepatic stem cells are a very small fraction of the liver cell population and give rise to proximal hepatic stem cells constituting a much larger fraction of the liver. Human proximal hepatic stem cells give rise to biliary and hepatocyte committed progenitors. Primitive and proximal stem cells are the primary stem cells for the human liver. Human primitive hepatic stem cells may be isolated by immunoselection from human livers or culturing human liver cells under conditions which select for a human primitive hepatic stem cell. Proximal hepatic stem cells may be isolated by immunoselection, or by culturing human liver cells under conditions which include a developmental factor.
    Type: Grant
    Filed: March 14, 2003
    Date of Patent: August 19, 2008
    Assignees: University of North Carolina at Chapel Hill, Vesta Therapeutics, Inc.
    Inventors: Lola M. Reid, Nicholas Moss, Mark Furth, John W. Ludlow, Andrew T. Bruce
  • Publication number: 20040110289
    Abstract: The present invention is directed toward a method for obtaining from whole liver or a resection thereof a population of cells comprising viable, functional liver cells enriched in hepatocytes and hepatocyte stem/progenitor cells, compositions thereof, and uses therefore. Compositions include a composition of liver cells enriched in hepatocytes and hepatocyte stem/progenitor cells and a pharmaceutical composition thereof. Uses include treatment of liver diseases, regeneration of liver, toxicity testing, and liver assist devices.
    Type: Application
    Filed: July 17, 2003
    Publication date: June 10, 2004
    Inventors: John W. Ludlow, Mark E. Furth, Andrew T. Bruce, Lola M. Reid, Robert L. Susick
  • Publication number: 20040018621
    Abstract: Hepatic progenitors comprise two populations of human hepatic stem cells, primitive and proximal hepatic stem cells, and two populations of committed progenitors, one for biliary cells and one for hepatocytes. Human primitive hepatic stem cells are a very small fraction of the liver cell population and give rise to proximal hepatic stem cells constituting a much larger fraction of the liver. Human proximal hepatic stem cells give rise to biliary and hepatocyte committed progenitors. Primitive and proximal stem cells are the primary stem cells for the human liver. Human primitive hepatic stem cells may be isolated by immunoselection from human livers or culturing human liver cells under conditions which select for a human primitive hepatic stem cell. Proximal hepatic stem cells may be isolated by immunoselection, or by culturing human liver cells under conditions which include a developmental factor.
    Type: Application
    Filed: March 14, 2003
    Publication date: January 29, 2004
    Inventors: Lola Reid, Nick Moss, Mark E. Furth, John W. Ludlow, Andrew T. Bruce